US Pharmaceutical Company Revises Yen Loan and Renews Contract with Japanese Mega Bank

On July 1, 2026, Viatris Inc. (NASDAQ: VTRS) entered into an amended and restated yen-denominated term loan agreement with Mizuho Bank, acting as administrative agent, and a Japanese banking syndicate, replacing its previous ¥40 billion (approximately KRW 400 billion) loan facility dated July 1, 2021.

The new agreement updates the definitions, borrowing mechanics, financial and operational covenants, events of default, certain affiliates’ and subsidiaries’ guarantee structures, and various administrative procedures. Mizuho Bank, MUFG Bank, and Sumitomo Mitsui Banking Corporation have been appointed joint lead arrangers and bookrunners, thereby reorganizing Viatris’s yen funding line.

In the first quarter of this year, Viatris reported revenue of approximately USD 3.5 billion (KRW 4–5 trillion), marking an 8% year-over-year increase. The company reaffirmed its full-year 2026 guidance and continued its post-restructuring recovery trend.

Viatris is a global pharmaceutical company headquartered in Canonsburg, Pennsylvania, formed in 2020 through the merger of generic drugmaker Mylan and Pfizer’s branded medicines division, Upjohn. It supplies generics, branded pharmaceuticals, and biosimilars to more than 160 countries.